May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Safety Profile of Topical VEGF-Neutralization at the Cornea Using Bevacizumab Eye Drops in a Murine Model
Author Affiliations & Notes
  • C. Cursiefen
    Dept of Ophthalmology, University of Erlangen Nuernberg, Erlangen, Germany
  • F. Bock
    Dept of Ophthalmology, University of Erlangen Nuernberg, Erlangen, Germany
  • T. Dietrich
    Dept of Ophthalmology, University of Erlangen Nuernberg, Erlangen, Germany
  • B. Bachmann
    Dept of Ophthalmology, University of Erlangen Nuernberg, Erlangen, Germany
  • C. Rummelt
    Dept of Ophthalmology, University of Erlangen Nuernberg, Erlangen, Germany
  • U. Schlötzer-Schrehardt
    Dept of Ophthalmology, University of Erlangen Nuernberg, Erlangen, Germany
  • F. E. Kruse
    Dept of Ophthalmology, University of Erlangen Nuernberg, Erlangen, Germany
  • Footnotes
    Commercial Relationships  C. Cursiefen, None; F. Bock, None; T. Dietrich, None; B. Bachmann, None; C. Rummelt, None; U. Schlötzer-Schrehardt, None; F.E. Kruse, None.
  • Footnotes
    Support  Interdisciplinary Center for Clinical Research (IZKF) Erlangen (A9)
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 1469. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      C. Cursiefen, F. Bock, T. Dietrich, B. Bachmann, C. Rummelt, U. Schlötzer-Schrehardt, F. E. Kruse; Safety Profile of Topical VEGF-Neutralization at the Cornea Using Bevacizumab Eye Drops in a Murine Model. Invest. Ophthalmol. Vis. Sci. 2008;49(13):1469. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Bevacizumab (Avastin®) eye drops potently inhibit corneal angiogenesis and lymphangiogenesis. Purpose of this study was to analyze whether Bevacizumab eye drops and thereby neutralization of VEGF-A at the ocular surface affect normal corneal integrity or corneal epithelial wound healing in vivo.

Methods: : Bevacizumab eye drops (5 mg/ml) were applied to normal murine corneas 5x/day for 7 and 14 days. Subsequently corneas were analyzed for morphological changes by light and electron microscopy. In a mouse model of corneal epithelial abrasion (central 1.8 mm2), we analyzed the effects of topically applied Bevacizumab on epithelial wound healing: the treatment group received Bevacizumab (5 mg/ml) as eye drops and the control group an equal volume of saline solution. After 12, 18 and 24 h corneas were photographed in vivo with and without fluorescein staining for morphometry. Afterwards the mice were sacrificed and eyes were removed for histology, immunohistochemistry with Ki67/DAPI and electronic microscopy.

Results: : Murine corneas treated with Bevacizumab eye drops did not show obvious corneal morphological changes at the light and electron microscopical level. Furthermore, Bevacizumab eye drops had no significant impact on the wound healing process after corneal epithelial injury.

Conclusions: : Short-time topical application of Bevacizumab eye drops at the cornea and thereby neutralization of VEGF-A at the corneal surface does not have significant side-effects on corneal epithelial wound healing nor on normal corneal integrity. Therefore, short-term Bevacizumab eye drops seem to be a safe option to treat corneal neovascularisation even in the presence of epithelial defects.

Keywords: cornea: clinical science • neovascularization • vascular endothelial growth factor 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×